Brief: Palisade Bio Receives Health Canada Clearance For Phase 1B Trial Of Pali-2108 In Fibrostenotic Crohn’S Disease (Fscd)
05/09/2025 15:56
Sept 5 (Reuters) - Palisade Bio Inc PALI.O: PALISADE BIO RECEIVES HEALTH CANADA CLEARANCE FOR PHASE 1B TRIAL OF PALI-2108 IN FIBROSTENOTIC CROHN’S DISEASE (FSCD) PALISADE BIO: PATIENT DOSING EXPECTED TO COMMENCE IN H2 2025; TOPLINE DATA ANTICIPATED IN Q1 2026 PALISADE BIO INC - PHASE 2 IND SUBMISSIONS FOR PALI-2108 EXPECTED IN Q1 2026 Source text: ID:nGNX1YX1kx Further company coverage: PALI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing